Valuation : Fulcrum Therapeutics, Inc.

Market Cap 291M 251M 236M 215M 402M 27.63B 404M 2.79B 1.08B 14.12B 1.09B 1.07B 44.77B P/E 2026 *
-6.13x
P/E 2027 * -7.76x
Enterprise Value -13.14M -11.31M -10.64M -9.71M -18.12M -1.25B -18.21M -126M -48.72M -637M -49.36M -48.27M -2.02B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
96.65%
Yield 2026 *
-
Yield 2027 * -
1 day-0.78%
1 week-1.80%
Current month-1.80%
1 month-1.80%
3 months+3.52%
6 months-53.24%
Current year-66.22%
1 week 3.8
Extreme 3.795
3.9
1 month 3.62
Extreme 3.615
3.94
Current year 2.83
Extreme 2.83
12.03
1 year 2.83
Extreme 2.83
15.74
3 years 2.32
Extreme 2.315
15.74
5 years 2.25
Extreme 2.25
33.1
10 years 2.25
Extreme 2.25
33.1
Manager TitleAgeSince
Chief Executive Officer 59 30/06/2023
Director of Finance/CFO 64 06/08/2023
Chief Tech/Sci/R&D Officer 63 30/11/2022
Director TitleAgeSince
Director/Board Member 71 18/07/2016
Director/Board Member 71 18/07/2016
Chairman 50 09/01/2022
Date Insider Type Main position Quantity % Market Cap. Importance
17/07/26
Tang Capital Management LLC
BuyCompany 50,945 0.0765%
15/07/26
Tang Capital Management LLC
BuyCompany 107,377 0.1611%
13/07/26
Tang Capital Management LLC
OtherCompany 6,663,383 10.0001%
Change 5-day change 1-year change 3-year change Capi.($)
-0.78%-1.80%-50.13%-31.17% 294M
-0.82%-3.57%-3.71%+12.92% 48.41B
-1.29%+0.85%+411.90%+546.06% 45.01B
-3.20%-0.76%+38.11%+18.36% 44.07B
-1.89%-2.25%+2.83%+80.93% 40.73B
-1.72%-3.07%+13.76%+43.40% 33.21B
-0.17%+2.68% - - 17.77B
-0.07%-0.52%+21.34%+117.49% 16.5B
-0.56%-1.85%+11.53%+30.40% 14.45B
-2.68%-2.60%+71.21%+37.36% 13.77B
Average -1.32%+0.18%+57.43%+95.08% 27.42B
Weighted average by Cap. -1.54%-0.12%+86.17%+131.16%

Financials

2026 *2027 *
Net sales - -
Net income -47.81M -41.13M -38.69M -35.31M -65.89M -4.53B -66.24M -458M -177M -2.32B -180M -176M -7.34B -39.14M -33.67M -31.67M -28.91M -53.94M -3.71B -54.22M -375M -145M -1.9B -147M -144M -6.01B
Net Debt -305M -262M -246M -225M -420M -28.88B -422M -2.92B -1.13B -14.76B -1.14B -1.12B -46.79B -296M -255M -240M -219M -408M -28.1B -411M -2.84B -1.1B -14.36B -1.11B -1.09B -45.53B
Logo Fulcrum Therapeutics, Inc.
Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with rare hematological disorders. The Company's lead clinical program is pociredir, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease (SCD). It uses proprietary technology to identify drug targets that can modulate gene expression to treat the known root cause of genetically defined diseases. In addition to its product candidates, the Company has developed a discovery approach to systematically identify and validate cellular drug targets that can potentially modulate gene expression to treat known root causes of genetically defined rare diseases. It also presented preclinical data for FTX-6274, an oral EED inhibitor candidate, demonstrating tumor growth inhibition in castration resistant prostate cancer models.
Employees
9
Date Price Change Volume
08/09/26 US$3.820 -0.78% 1,109,046
04/09/26 US$3.850 +0.26% 1,004,739
03/09/26 US$3.840 -0.26% 1,436,135
02/09/26 US$3.850 -0.52% 1,633,566
01/09/26 US$3.870 -0.51% 1,681,873
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
6
Last Close Price
3.820USD
Average target price
3.500USD
Spread / Average Target
-8.38%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. FULC Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!